Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

97.12 -1.54 (-1.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,303,693
Open 99.01
Bid (Size) 98.75 (5)
Ask (Size) 102.00 (10)
Prev. Close 98.66
Today's Range 97.00 - 99.56
52wk Range 70.73 - 100.30
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Expert Ratings for Biomarin Pharmaceutical
 
Via Benzinga

Performance

YTD
+8.68%
+8.68%
1 Month
+12.11%
+12.11%
3 Month
+7.52%
+7.52%
6 Month
+29.27%
+29.27%
1 Year
+11.12%
+11.12%

More News

Read More
Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate
Via Benzinga
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
Via Investor's Business Daily
Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today
Via Benzinga
$1.4 Million Bet On This Real Estate Stock? 3 Stocks Insiders Are Buying
Via Benzinga
Expert Ratings for Biomarin Pharmaceutical
Via Benzinga
Why BioMarin Pharmaceuticals Fell 6.9% on Thursday
Via The Motley Fool
Expert Ratings for Biomarin Pharmaceutical
Via Benzinga
10 Analysts Have This to Say About Biomarin Pharmaceutical
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Via Benzinga
Mastercard To $428? Plus This Analyst Slashes PT On Intel
Via Benzinga
One Rejected BioMarin's Hemophilia Gene Therapy Goes Under FDA Review
Via Benzinga
BioMarin Lays Off 4% Of Its Workforce To 'Simplify' The Company
Via Benzinga
Biomarin Pharmaceutical: Q3 Earnings Insights
Via Benzinga
Recap: Biomarin Pharmaceutical Q3 Earnings
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
Via Investor's Business Daily
BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial
Via Benzinga
Neurocrine Leads 5 Stocks To Watch In Sickly Market
Via Investor's Business Daily
Expert Ratings for Biomarin Pharmaceutical
Via Benzinga
BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
BioMarin Receives European Commission's Conditional Marketing Authorization For Gene Therapy Candidate
Via Benzinga
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.